The Use of CRISPR/Cas9 Technology in Engineering Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy for the Treatment of Cancer in Brazil

被引：0
|
作者：
Carvalho, Julia [1 ]
Cupello, Mauricio [2 ]
Medina, Romulo [2 ]
机构：
[1] INCA, Rio De Janeiro, Brazil
[2] Unigranrio, Rio De Janeiro, Brazil
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CAR-T; CRISPR/Cas9; Brazil; gene editing; universal CAR-T cells;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-312
引用
收藏
页码：S525 / S526
页数：2
相关论文
共 50 条
  • [1] Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
    Jiangtao Ren
    Yangbing Zhao
    Protein & Cell, 2017, 8 (09) : 634 - 643
  • [2] Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
    Ren, Jiangtao
    Zhao, Yangbing
    PROTEIN & CELL, 2017, 8 (09) : 634 - 643
  • [3] Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
    Mo, Fengzhen
    Duan, Siliang
    Jiang, Xiaobing
    Yang, Xiaomei
    Hou, Xiaoqiong
    Shi, Wei
    Carlos, Cueva Jumbo Juan
    Liu, Aiqun
    Yin, Shihua
    Wang, Wu
    Yao, Hua
    Yu, Zihang
    Tang, Zhuoran
    Xie, Shenxia
    Ding, Ziqiang
    Zhao, Xinyue
    Hammock, Bruce D.
    Lu, Xiaoling
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [4] Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
    Fengzhen Mo
    Siliang Duan
    Xiaobing Jiang
    Xiaomei Yang
    Xiaoqiong Hou
    Wei Shi
    Cueva Jumbo Juan Carlos
    Aiqun Liu
    Shihua Yin
    Wu Wang
    Hua Yao
    Zihang Yu
    Zhuoran Tang
    Shenxia Xie
    Ziqiang Ding
    Xinyue Zhao
    Bruce D. Hammock
    Xiaoling Lu
    Signal Transduction and Targeted Therapy, 6
  • [5] Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges
    Zhi, Lingtong
    Su, Xin
    Yin, Meichen
    Zhang, Zikang
    Lu, Hui
    Niu, Zhiyuan
    Guo, Changjiang
    Zhu, Wuling
    Zhang, Xuan
    CELLULAR IMMUNOLOGY, 2021, 369
  • [6] Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy
    Shu, Runzhe
    Hammett, Maree
    Evtimov, Vera
    Pupovac, Aleta
    Nguyen, Nhu-Y
    Islam, Rasa
    Zhuang, Junli
    Lee, Seyeong
    Kang, Tae-hun
    Lee, Kyujun
    Nisbet, Ian
    Hudson, Peter
    Lee, Jae Young
    Boyd, Richard
    Trounson, Alan
    BIOENGINEERING & TRANSLATIONAL MEDICINE, 2023, 8 (06)
  • [7] Improving CAR-T cell immunotherapy with CRISPR/Cas9 gene editing
    Sarac, Andrea
    Ogorelec, Karen Butina
    Pohar, Jelka
    Horvat, Simon
    Smole, Anze
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 746 - 746
  • [8] Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology
    Tao, Ruiyu
    Han, Xiaopeng
    Bai, Xue
    Yu, Jianping
    Ma, Youwei
    Chen, Weikai
    Zhang, Dawei
    Li, Zhengkai
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [9] CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment
    Mollanoori, Hasan
    Shahraki, Hojat
    Rahmati, Yazdan
    Teimourian, Shahram
    HUMAN IMMUNOLOGY, 2018, 79 (12) : 876 - 882
  • [10] Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9
    Amiri, Maryam
    Moaveni, Amir Kian
    Zolbin, Masoumeh Majidi
    Shademan, Behrouz
    Nourazarian, Alireza
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345